Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein.
暂无分享,去创建一个
J. Bissler | A. Davis | C. Andreadis | J. Wisnieski | R. Zahedi | Alvin E. Davis | Rana Zahedi | John J. Bissler | Charalambos Andreadis
[1] D. Dearborn,et al. Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r. , 1994, Journal of immunology.
[2] C. Hack,et al. A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. , 1993, The Journal of biological chemistry.
[3] C. Hack,et al. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms , 1992, Nature Genetics.
[4] R. Harrison,et al. A dysfunctional Cl inhibitor protein with a new reactive center mutation (Arg‐444→Leu) , 1992, FEBS letters.
[5] C. Hack,et al. Characterization of recombinant C1 inhibitor P1 variants. , 1992, The Journal of biological chemistry.
[6] W. R. Wikoff,et al. Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status. , 1991, The Journal of biological chemistry.
[7] J. York,et al. Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor I. , 1991, The Journal of biological chemistry.
[8] P. Carter,et al. Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of Alu elements. , 1991, European journal of biochemistry.
[9] K. Aulak,et al. Rapid and sensitive techniques for identification and analysis of 'reactive-centre' mutants of C1-inhibitor proteins contained in type II hereditary angio-oedema plasmas. , 1990, The Biochemical journal.
[10] N. Roodi,et al. Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems. , 1990, The Journal of biological chemistry.
[11] M. Cicardi,et al. Identification of a new P1 residue mutation (444Arg→Ser) in a dysfunctional C1 inhibitor protein contained in a type II hereditary angioedema plasma , 1990, FEBS letters.
[12] P. Stein,et al. Ovalbumin and angiotensinogen lack serpin S-R conformational change. , 1989, The Biochemical journal.
[13] N. Thielens,et al. Structure and function of C1r and C1s: current concepts. , 1989, Behring Institute Mitteilungen.
[14] K. Skriver,et al. CpG mutations in the reactive site of human C1 inhibitor. , 1989, The Journal of biological chemistry.
[15] P. Lachmann,et al. The structural basis for neutrophil inactivation of C1 inhibitor. , 1989, The Biochemical journal.
[16] Wisnieski Jj,et al. Plasma kinetics of complement component C4: comparison of three models. , 1989 .
[17] M. Nathanson,et al. Plasma kinetics of complement component C4: comparison of three models. , 1989, The Journal of laboratory and clinical medicine.
[18] C. Hack,et al. Expression of functional human C1 inhibitor in COS cells. , 1988, The Journal of biological chemistry.
[19] F. Rosen,et al. Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation. , 1988, The Biochemical journal.
[20] A. Davis. C1 inhibitor and hereditary angioneurotic edema. , 1988, Annual review of immunology.
[21] A. Davis,et al. Metabolism of C4 and linkage analysis in a kindred with hereditary incomplete C4 deficiency. , 1987, Arthritis and rheumatism.
[22] F. Rosen,et al. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies , 1987 .
[23] R. Huber,et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. , 1986, Biochemistry.
[24] J H Lewis,et al. Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf. , 1986, The Journal of clinical investigation.
[25] M. Schapira,et al. Recombinant alpha 1-antitrypsin Pittsburgh (Met 358----Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment. , 1986, The Journal of clinical investigation.
[26] J. Catanese,et al. Primary structure of the reactive site of human C1-inhibitor. , 1985, The Journal of biological chemistry.
[27] F. Rosen,et al. Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies. , 1985, The Journal of clinical investigation.
[28] S. Hedrick,et al. Inherited incomplete deficiency of the fourth component of complement (C4) determined by a gene not linked to human histocompatibility leukocyte antigens. , 1984, The Journal of clinical investigation.
[29] J H Lewis,et al. Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. , 1983, The New England journal of medicine.
[30] T. Lin,et al. Mapping the substrate binding site of human C1r and C1s with peptide thioesters. Development of new sensitive substrates. , 1981, The Journal of biological chemistry.
[31] W. Rutter,et al. Polymorphic DNA region adjacent to the 5' end of the human insulin gene. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[32] Robert B Sim,et al. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s. , 1980, Biochimica et biophysica acta.
[33] F. Sanger,et al. DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.